Persistent Platelet Reactivity in Acute Coronary Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndrome
- Sponsor
- Hopital Lariboisière
- Enrollment
- 106
- Locations
- 1
- Primary Endpoint
- maximum aggregation intensity
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Study of persistent platelet reactivity during acute coronary syndrome. Patients are included at admission to the hospital. Platelet aggregation is evaluated by platelet function testing after blood sampling during hospitalization. No changes in treatment is planned.
Detailed Description
Blood samples are performed on day 2 and 4 and collected with usual blood samples and analyzed by the laboratory. Maximal aggregation intensity and velocity are measured by light transmission aggregometry induced by arachidonic acid (AA) or adenosine diphosphate (ADP). Platelet function analyzer will be also used. No changes in treatment in response to the results is planned.
Investigators
Dr Jean-Guillaume DILLINGER
Department of Cardiology
Hopital Lariboisière
Eligibility Criteria
Inclusion Criteria
- •acute coronary syndrome with elevation in troponin
Exclusion Criteria
- •anticoagulant treatment
Outcomes
Primary Outcomes
maximum aggregation intensity
Time Frame: day 2
Light transmission aggregometry following exposition to arachidonic acid 0.5mg/ml during the acute phase (day2-day 5)
Secondary Outcomes
- Maximum aggregation intensity(Chronic phase (day 30 to day 60))